SMOORE Launches Real-Time Monitoring Study on Nicotine Addiction

Jul.07.2022
SMOORE Launches Real-Time Monitoring Study on Nicotine Addiction
The world's largest e-cigarette manufacturer, SMOORE, partners with SIAT to study nicotine addiction and reduce nicotine levels in e-cigarettes.

The world's largest electronic cigarette manufacturer, SMOORE, has announced the launch of the world's first real-time monitoring research project on nicotine addiction.


The vaporization process between e-cigarettes and combustible cigarettes is vastly different, resulting in distinct physical and chemical properties obtained from vaporization and tobacco combustion, respectively.


Electronic cigarette company, SMOORE, has partnered with the Shenzhen Institute of Advanced Technology (SIAT) to undertake a new research project aimed at exploring ways to significantly reduce the nicotine strength in electronic cigarette products and ultimately lower it to non-addictive levels.


Under the direction of Nobel laureate Dr. Erwin Neher, the Neher Laboratory for Neural Plasticity in Shenzhen is the sixth laboratory in Shenzhen named after a Nobel laureate and the first dedicated to neuroscience. The laboratory focuses on researching the human brain and aims to better understand the mechanisms behind diseases and addictions through the use of the latest advanced techniques in modern neuroscience.


This joint study will investigate the secretion and metabolism of dopamine in the brains of animals, and use the data gathered to simulate the human brain state when nicotine is consumed. The laboratory will conduct controlled experiments by exposing test subjects to aerosol environments created by FEELM vaporization and combustion of tobacco.


The project aims to reduce the nicotine intake and subsequent dependence in adult e-cigarette users. This study will also assist SMOORE's research and development team in enhancing the design of e-cigarette devices by improving efficiency through modifying heating elements and atomizers to enhance the vaping experience.


Researchers involved in the project will monitor the aerosolization of e-liquid to gain a better understanding of nicotine absorption, distribution, metabolism in the human body. Additionally, the study will investigate how nicotine is absorbed by different organs to reveal the sensory satisfaction of e-cigarettes.


Dr. Xiong Yuming, Vice President of SMOORE Shenzhen Institute of Basic Research, stated that...


The process of vaporization between electronic cigarettes and combustible cigarettes is vastly different. Therefore, the physical and chemical properties obtained from vaporization and tobacco burning are also completely different. Our study focuses on the potential mechanisms of vaporization and tobacco burning, with the aim of exploring the delivery and absorption of nicotine to reduce the impact of these products on health.


This project is being supported by Southwest University in Chongqing, China. A phased report is expected to be released in the second half of 2022, which will outline the different effects of nicotine on the brain in electronic cigarettes and combustible tobacco products. This joint study on nicotine dependency aims to put an end to global nicotine addiction. Looking towards the future, FEELM aims to provide products that do not lead to nicotine dependency by reducing nicotine levels as close to zero as possible without compromising satisfaction.


This article is a compilation of third-party information, intended for educational and informational purposes only. The copyright for the compiled information belongs to the original media and authors. If there are any copyright infringements, please contact us for removal.



Disclaimer

This article is provided solely for professional research, industry discussion, and informational purposes. Any references to brands, companies, products, technologies, or policies are made for factual reporting and analytical purposes only, and do not constitute endorsement, recommendation, promotion, or advertising by 2Firsts.

Nicotine-containing products, including but not limited to cigarettes, e-cigarettes, heated tobacco products, and nicotine pouches, carry significant health risks. Readers are responsible for complying with all applicable laws and regulations in their respective jurisdictions, including age restrictions and access limitations.

The information contained in this article should not be regarded as investment, legal, medical, regulatory, or commercial advice. While 2Firsts strives to ensure the accuracy and reliability of its content, it does not assume liability for any direct or indirect loss arising from errors, omissions, inaccuracies, or reliance on the information contained herein.

This article is not intended for individuals below the legal age for accessing tobacco or nicotine-related information in their jurisdiction.

 

Copyright Notice

This article is either original content produced by 2Firsts or content reproduced, translated, summarized, or adapted from third-party sources with attribution where applicable. The intellectual property rights of the original content remain with 2Firsts or the respective original rights holders.

No individual or organization may copy, reproduce, distribute, republish, modify, translate, or otherwise use this content without prior authorization. Any unauthorized use may result in legal action.

For copyright-related inquiries, corrections, or removal requests, please contact: info@2firsts.com.

 

AI-Assisted Translation and Editing Notice

Portions of this article may have been translated, edited, or reviewed with the assistance of artificial intelligence tools to improve efficiency and readability. Due to the limitations of AI-assisted translation and editing, discrepancies, omissions, or inaccuracies may exist when compared with the original source.

Where applicable, readers are advised to refer to the original source for the most complete and accurate information. If you identify any errors or believe that any content infringes upon your rights, please contact us at info@2firsts.com, and we will review and address the matter promptly.

FDA Authorizes Four More Nicotine Pouches as Review Pilot Expands Beyond Initial Decisions
FDA Authorizes Four More Nicotine Pouches as Review Pilot Expands Beyond Initial Decisions
The FDA has authorized four additional on! nicotine pouches, bringing the U.S. total to 30. The decision marks another outcome of the agency’s nicotine pouch review pilot, whose communication and review practices are now being applied more broadly across the category. It also extends Helix’s authorized portfolio from on! PLUS to the earlier on! line. Yet all FDA-authorized nicotine pouches still come from subsidiaries of PMI or Altria, underscoring how concentrated U.S. regulatory access remains.
Aug.05
IQOS Global Flagship Space to Open in Tokyo Ginza as PMI Expands Consumer Experience Strategy
IQOS Global Flagship Space to Open in Tokyo Ginza as PMI Expands Consumer Experience Strategy
Philip Morris Japan (PMJ) announced that it will open “IQOS Flagship Ginza” in Tokyo on September 4, 2026. The location will become the first global flagship space for PMI’s IQOS brand. PMJ said the venue will target adult smokers aged 20 and above and combine product experiences, community engagement and local cultural elements. The design will incorporate Japanese natural aesthetics and traditional craftsmanship. The launch reflects PMI’s broader strategy of strengthening consumer engagement through experiential retail and brand spaces. The existing IQOS Store Ginza is scheduled to close on August 30, 2026.
Jul.21
Alaska Warns 1,500 Tobacco Retailers Over Unauthorized Vapes and Nicotine Pouches
Alaska Warns 1,500 Tobacco Retailers Over Unauthorized Vapes and Nicotine Pouches
Alaska Attorney General Stephen J. Cox has sent notices to more than 1,500 tobacco retailers and distributors warning them against selling vape and nicotine pouch products that lack authorization from the U.S. Food and Drug Administration (FDA). According to the Alaska Department of Law, businesses were advised to verify products against FDA authorization databases and avoid selling unauthorized nicotine products. The action highlights how state-level enforcement is increasingly extending federal product authorization requirements to retail channels.
Jul.24
BREAKING | China’s Tobacco Regulator Summons iMiracle Over Suspected Compliance Breaches
BREAKING | China’s Tobacco Regulator Summons iMiracle Over Suspected Compliance Breaches
Based on public records reviewed by 2Firsts, this is the first time China’s State Tobacco Monopoly Administration has publicly announced regulatory talks with an e-cigarette company.
Jul.29
UK HMRC Urges Public to Report Suspicious Vape Shops in Crackdown on Tax Fraud, Money Laundering and Illicit Tobacco Sales
UK HMRC Urges Public to Report Suspicious Vape Shops in Crackdown on Tax Fraud, Money Laundering and Illicit Tobacco Sales
HM Revenue & Customs is urging members of the public to report vape shops, barber shops and other high-street businesses suspected of tax fraud, money laundering or other illegal activity, with informants not required to provide personal details. HMRC plans more than 30,000 interventions in 2026-27 targeting tax fraud, organised crime and illicit activity, including the sale of illegal vapes and tobacco. The push forms part of a broader UK effort to tackle organised crime on high streets, backed by a £30 million government enforcement programme.
Regulations
Aug.17 by 2Firsts Perspectives
From Nicotine Salts to Cocrystals: China’s Shenzhen Huabao institute explores a more stable form for sustained nicotine release
From Nicotine Salts to Cocrystals: China’s Shenzhen Huabao institute explores a more stable form for sustained nicotine release
China-based Shenzhen Huabao Collaborative Innovation Technology Research Institute Co., Ltd. has filed a patent application for a nicotine-ascorbic acid cocrystal, exploring a new solid-state form of nicotine. The patent proposes applications across e-liquids, heated tobacco sticks, oral tobacco, chewing tobacco and snuff. In nicotine pouch tests disclosed in the filing, cocrystal formulations showed less than a 6% decline in nicotine content after three months of accelerated storage and a release profile combining early-stage release with sustained delivery over 60 minutes. The filing reflects exploration of nicotine forms beyond conventional nicotine base and nicotine salts.
Aug.13